Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021

Michael Edelstein; Karine Wiegler Beiruti; Hila Ben-Amram; Naor Bar-Zeev; Christian Sussan; Hani Asulin; David Strauss; Younes Bathish; Salman Zarka; Kamal Abu Jabal

doi:10.1093/cid/ciac212

Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021

Michael Edelstein, Karine Wiegler Beiruti, Hila Ben-Amram, Naor Bar-Zeev, Christian Sussan, Hani Asulin, David Strauss, Younes Bathish, Salman Zarka, Kamal Abu Jabal

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: We determined circulating anti-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody titers in a vaccinated healthcare workers (HCWs) cohort from Northern Israel in the 11 months following primary vaccination according to age, ethnicity, and previous infection status. METHODS: All consenting HCWs were invited to have their IgG levels measured before vaccination and at 6 subsequent timepoints using a quantitative S1/S2 IgG assay. All HCWs with suspected coronavirus disease 2019 (COVID-19) were polymerase chain reaction (PCR) tested. We described trends in circulating IgG geometric mean concentration (GMC) by age, ethnicity, timing of boosting, and previous infection status and compared strata using Kruskall-Wallis tests. RESULTS: Among 985 vaccinated HCWs, IgG titers between 1 month post 2nd dose to pre-boosting gradually decreased in all age groups. Younger or previously infected individuals had higher initial post-vaccination IgG levels (P < .001 in both cases); differences substantially decreased or disappeared at 7-9 months, before boosting. The proportion of individuals infected prior to initiating vaccination and re-infected after dose 1 was comparable to the proportion of breakthrough infection post-dose 2 in those not previously infected (4.2 vs 4.7%). Pre-infection IgG levels in the 40 participants with breakthrough infection after dose 2 were similar to levels measured at the same timepoint in vaccinated HCWs who remained uninfected (P > .3). Post-dose3 IgG levels were more than 10-fold those 1 month post-dose 2. CONCLUSIONS: Immunity waned in all age groups and previously infected individuals, reversed by boosting. IgG titers decrease and reinfections in individuals with hybrid immunity (infection + vaccination) suggests they may also require further doses. Our study also highlights the difficulty in determining protective IgG levels.

Original language	English
Pages (from-to)	e572-e578
Journal	Clinical Infectious Diseases
Volume	75
Issue number	1
DOIs	https://doi.org/10.1093/cid/ciac212
State	Published - 24 Aug 2022
Externally published	Yes

Bibliographical note

Funding Information:
Z.M. was supported by The Single Cell Gene Expression Atlas grant 108437/Z/15/Z from the Wellcome Trust. E.W. was supported by the French National Program Investissement d’Avenir (Labex NetRNA) administered by the Agence National de la Recherche (ANR-10-LABX-0036_NETRNA). Y.X. was supported by NSFC under Grant No. 31570722 and 11874162. M.S. and her group were supported by the Polish National Science Center (NCN; 2016/23/B/ST6/03931) and by the statutory funds of Poznan University of Technology, Poland. S-J.C was supported by NIH R01-GM117059 (S.-J.C) and NIH R01-GM063732 (S.-J.C). R.D. and his group were supported by NIH R35 GM122579 and R21 CA219847. D.M.J.L. group was funded by Cancer Research UK program grant A18604. R.T.B. and his group were funded by NIH R01-GM073850. J.M.B. and his group were supported by the Polish National Science Center (NCN; 2012/04/A/NZ2/ 00455 to J.M.B. and 2015/17/N/NZ2/03360 to M.M), and by the Foundation for Polish Science (FNP; POIR.04.04.00-00-3CF0/16). Support from the National Institutes for Health (5R01GM123247, 2R01 GM114015, and 1R35 GM134864 to N.V.D.) and the Passan Foundation are acknowledged. The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 (J.W. and N.V.D.). Funding for the open access charge was provided by Shanghai Fourth People’s Hospital. The authors thank the Lee group at the Korea Institute for Advanced Study and an anonymous group for their participation in RNA-Puzzles. The authors also thank the members of the Bujnicki group for technical contributions, including Stanisław Dunin-Horkawicz (IIMCB), Grzegorz Chojnowski (IIMCB), Wayne Dawson (IIMCB), Dorota Matelska (IIMCB), Catarina Almeida (IIMCB), Bharat Madan (IIMCB), Grzegorz Lach (IIMCB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Funding Information:
Z.M. was supported by The Single Cell Gene Expression Atlas grant 108437/Z/15/Z from the Wellcome Trust. E.W. was supported by the French National Program Investissement d'Avenir (Labex NetRNA) administered by the Agence National de la Recherche (ANR-10-LABX-0036_NETRNA). Y.X. was supported by NSFC under Grant No. 31570722 and 11874162. M.S. and her group were supported by the Polish National Science Center (NCN; 2016/23/B/ST6/03931) and by the statutory funds of Poznan University of Technology, Poland. S-J.C was supported by NIH R01-GM117059 (S.-J.C) and NIH R01-GM063732 (S.-J.C). R.D. and his group were supported by NIH R35 GM122579 and R21 CA219847. D.M.J.L. group was funded by Cancer Research UK program grant A18604. R.T.B. and his group were funded by NIH R01-GM073850. J.M.B. and his group were supported by the Polish National Science Center (NCN; 2012/04/A/NZ2/ 00455 to J.M.B. and 2015/17/N/NZ2/03360 to M.M), and by the Foundation for Polish Science (FNP; POIR.04.04.00-00-3CF0/16). Support from the National Institutes for Health (5R01GM123247, 2R01 GM114015, and 1R35 GM134864 to N.V.D.) and the Passan Foundation are acknowledged. The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 (J.W. and N.V.D.). Funding for the open access charge was provided by Shanghai Fourth People's Hospital. The authors thank the Lee group at the Korea Institute for Advanced Study and an anonymous group for their participation in RNA-Puzzles. The authors also thank the members of the Bujnicki group for technical contributions, including Stanis?aw Dunin-Horkawicz (IIMCB), Grzegorz Chojnowski (IIMCB), Wayne Dawson (IIMCB), Dorota Matelska (IIMCB), Catarina Almeida (IIMCB), Bharat Madan (IIMCB), Grzegorz Lach (IIMCB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Author contributions: E.W. conceived and supervised the project, coordinated the collaboration, and wrote the manuscript. Z.M. organized the prediction, analyzed the results, built the website, and wrote the manuscript. All other authors predicted the structures, analyzed the results, and wrote the manuscript.

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.

Keywords

COVID-19
Israel
SARS-CoV-2
vaccine immunogenicity
vaccines

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciac212

Fingerprint

Dive into the research topics of 'Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021'. Together they form a unique fingerprint.

Cite this

Edelstein, M., Wiegler Beiruti, K., Ben-Amram, H., Bar-Zeev, N., Sussan, C., Asulin, H., Strauss, D., Bathish, Y., Zarka, S., & Abu Jabal, K. (2022). Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021. Clinical Infectious Diseases, 75(1), e572-e578. https://doi.org/10.1093/cid/ciac212

Edelstein, Michael ; Wiegler Beiruti, Karine ; Ben-Amram, Hila et al. / Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity : Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021. In: Clinical Infectious Diseases. 2022 ; Vol. 75, No. 1. pp. e572-e578.

@article{76c42aa6c74a47859bb1b4b067502929,

title = "Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021",

abstract = "BACKGROUND: We determined circulating anti-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody titers in a vaccinated healthcare workers (HCWs) cohort from Northern Israel in the 11 months following primary vaccination according to age, ethnicity, and previous infection status. METHODS: All consenting HCWs were invited to have their IgG levels measured before vaccination and at 6 subsequent timepoints using a quantitative S1/S2 IgG assay. All HCWs with suspected coronavirus disease 2019 (COVID-19) were polymerase chain reaction (PCR) tested. We described trends in circulating IgG geometric mean concentration (GMC) by age, ethnicity, timing of boosting, and previous infection status and compared strata using Kruskall-Wallis tests. RESULTS: Among 985 vaccinated HCWs, IgG titers between 1 month post 2nd dose to pre-boosting gradually decreased in all age groups. Younger or previously infected individuals had higher initial post-vaccination IgG levels (P < .001 in both cases); differences substantially decreased or disappeared at 7-9 months, before boosting. The proportion of individuals infected prior to initiating vaccination and re-infected after dose 1 was comparable to the proportion of breakthrough infection post-dose 2 in those not previously infected (4.2 vs 4.7%). Pre-infection IgG levels in the 40 participants with breakthrough infection after dose 2 were similar to levels measured at the same timepoint in vaccinated HCWs who remained uninfected (P > .3). Post-dose3 IgG levels were more than 10-fold those 1 month post-dose 2. CONCLUSIONS: Immunity waned in all age groups and previously infected individuals, reversed by boosting. IgG titers decrease and reinfections in individuals with hybrid immunity (infection + vaccination) suggests they may also require further doses. Our study also highlights the difficulty in determining protective IgG levels.",

keywords = "COVID-19, Israel, SARS-CoV-2, vaccine immunogenicity, vaccines",

author = "Michael Edelstein and {Wiegler Beiruti}, Karine and Hila Ben-Amram and Naor Bar-Zeev and Christian Sussan and Hani Asulin and David Strauss and Younes Bathish and Salman Zarka and {Abu Jabal}, Kamal",

note = "Funding Information: Z.M. was supported by The Single Cell Gene Expression Atlas grant 108437/Z/15/Z from the Wellcome Trust. E.W. was supported by the French National Program Investissement d{\textquoteright}Avenir (Labex NetRNA) administered by the Agence National de la Recherche (ANR-10-LABX-0036_NETRNA). Y.X. was supported by NSFC under Grant No. 31570722 and 11874162. M.S. and her group were supported by the Polish National Science Center (NCN; 2016/23/B/ST6/03931) and by the statutory funds of Poznan University of Technology, Poland. S-J.C was supported by NIH R01-GM117059 (S.-J.C) and NIH R01-GM063732 (S.-J.C). R.D. and his group were supported by NIH R35 GM122579 and R21 CA219847. D.M.J.L. group was funded by Cancer Research UK program grant A18604. R.T.B. and his group were funded by NIH R01-GM073850. J.M.B. and his group were supported by the Polish National Science Center (NCN; 2012/04/A/NZ2/ 00455 to J.M.B. and 2015/17/N/NZ2/03360 to M.M), and by the Foundation for Polish Science (FNP; POIR.04.04.00-00-3CF0/16). Support from the National Institutes for Health (5R01GM123247, 2R01 GM114015, and 1R35 GM134864 to N.V.D.) and the Passan Foundation are acknowledged. The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 (J.W. and N.V.D.). Funding for the open access charge was provided by Shanghai Fourth People{\textquoteright}s Hospital. The authors thank the Lee group at the Korea Institute for Advanced Study and an anonymous group for their participation in RNA-Puzzles. The authors also thank the members of the Bujnicki group for technical contributions, including Stanis{\l}aw Dunin-Horkawicz (IIMCB), Grzegorz Chojnowski (IIMCB), Wayne Dawson (IIMCB), Dorota Matelska (IIMCB), Catarina Almeida (IIMCB), Bharat Madan (IIMCB), Grzegorz Lach (IIMCB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: Z.M. was supported by The Single Cell Gene Expression Atlas grant 108437/Z/15/Z from the Wellcome Trust. E.W. was supported by the French National Program Investissement d'Avenir (Labex NetRNA) administered by the Agence National de la Recherche (ANR-10-LABX-0036_NETRNA). Y.X. was supported by NSFC under Grant No. 31570722 and 11874162. M.S. and her group were supported by the Polish National Science Center (NCN; 2016/23/B/ST6/03931) and by the statutory funds of Poznan University of Technology, Poland. S-J.C was supported by NIH R01-GM117059 (S.-J.C) and NIH R01-GM063732 (S.-J.C). R.D. and his group were supported by NIH R35 GM122579 and R21 CA219847. D.M.J.L. group was funded by Cancer Research UK program grant A18604. R.T.B. and his group were funded by NIH R01-GM073850. J.M.B. and his group were supported by the Polish National Science Center (NCN; 2012/04/A/NZ2/ 00455 to J.M.B. and 2015/17/N/NZ2/03360 to M.M), and by the Foundation for Polish Science (FNP; POIR.04.04.00-00-3CF0/16). Support from the National Institutes for Health (5R01GM123247, 2R01 GM114015, and 1R35 GM134864 to N.V.D.) and the Passan Foundation are acknowledged. The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 (J.W. and N.V.D.). Funding for the open access charge was provided by Shanghai Fourth People's Hospital. The authors thank the Lee group at the Korea Institute for Advanced Study and an anonymous group for their participation in RNA-Puzzles. The authors also thank the members of the Bujnicki group for technical contributions, including Stanis?aw Dunin-Horkawicz (IIMCB), Grzegorz Chojnowski (IIMCB), Wayne Dawson (IIMCB), Dorota Matelska (IIMCB), Catarina Almeida (IIMCB), Bharat Madan (IIMCB), Grzegorz Lach (IIMCB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Author contributions: E.W. conceived and supervised the project, coordinated the collaboration, and wrote the manuscript. Z.M. organized the prediction, analyzed the results, built the website, and wrote the manuscript. All other authors predicted the structures, analyzed the results, and wrote the manuscript. Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2022",

month = aug,

day = "24",

doi = "10.1093/cid/ciac212",

language = "English",

volume = "75",

pages = "e572--e578",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

Edelstein, M, Wiegler Beiruti, K, Ben-Amram, H, Bar-Zeev, N, Sussan, C, Asulin, H, Strauss, D, Bathish, Y, Zarka, S & Abu Jabal, K 2022, 'Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021', Clinical Infectious Diseases, vol. 75, no. 1, pp. e572-e578. https://doi.org/10.1093/cid/ciac212

Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021. / Edelstein, Michael; Wiegler Beiruti, Karine; Ben-Amram, Hila et al.
In: Clinical Infectious Diseases, Vol. 75, No. 1, 24.08.2022, p. e572-e578.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity

T2 - Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021

AU - Edelstein, Michael

AU - Wiegler Beiruti, Karine

AU - Ben-Amram, Hila

AU - Bar-Zeev, Naor

AU - Sussan, Christian

AU - Asulin, Hani

AU - Strauss, David

AU - Bathish, Younes

AU - Zarka, Salman

AU - Abu Jabal, Kamal

N1 - Funding Information: Z.M. was supported by The Single Cell Gene Expression Atlas grant 108437/Z/15/Z from the Wellcome Trust. E.W. was supported by the French National Program Investissement d’Avenir (Labex NetRNA) administered by the Agence National de la Recherche (ANR-10-LABX-0036_NETRNA). Y.X. was supported by NSFC under Grant No. 31570722 and 11874162. M.S. and her group were supported by the Polish National Science Center (NCN; 2016/23/B/ST6/03931) and by the statutory funds of Poznan University of Technology, Poland. S-J.C was supported by NIH R01-GM117059 (S.-J.C) and NIH R01-GM063732 (S.-J.C). R.D. and his group were supported by NIH R35 GM122579 and R21 CA219847. D.M.J.L. group was funded by Cancer Research UK program grant A18604. R.T.B. and his group were funded by NIH R01-GM073850. J.M.B. and his group were supported by the Polish National Science Center (NCN; 2012/04/A/NZ2/ 00455 to J.M.B. and 2015/17/N/NZ2/03360 to M.M), and by the Foundation for Polish Science (FNP; POIR.04.04.00-00-3CF0/16). Support from the National Institutes for Health (5R01GM123247, 2R01 GM114015, and 1R35 GM134864 to N.V.D.) and the Passan Foundation are acknowledged. The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 (J.W. and N.V.D.). Funding for the open access charge was provided by Shanghai Fourth People’s Hospital. The authors thank the Lee group at the Korea Institute for Advanced Study and an anonymous group for their participation in RNA-Puzzles. The authors also thank the members of the Bujnicki group for technical contributions, including Stanisław Dunin-Horkawicz (IIMCB), Grzegorz Chojnowski (IIMCB), Wayne Dawson (IIMCB), Dorota Matelska (IIMCB), Catarina Almeida (IIMCB), Bharat Madan (IIMCB), Grzegorz Lach (IIMCB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: Z.M. was supported by The Single Cell Gene Expression Atlas grant 108437/Z/15/Z from the Wellcome Trust. E.W. was supported by the French National Program Investissement d'Avenir (Labex NetRNA) administered by the Agence National de la Recherche (ANR-10-LABX-0036_NETRNA). Y.X. was supported by NSFC under Grant No. 31570722 and 11874162. M.S. and her group were supported by the Polish National Science Center (NCN; 2016/23/B/ST6/03931) and by the statutory funds of Poznan University of Technology, Poland. S-J.C was supported by NIH R01-GM117059 (S.-J.C) and NIH R01-GM063732 (S.-J.C). R.D. and his group were supported by NIH R35 GM122579 and R21 CA219847. D.M.J.L. group was funded by Cancer Research UK program grant A18604. R.T.B. and his group were funded by NIH R01-GM073850. J.M.B. and his group were supported by the Polish National Science Center (NCN; 2012/04/A/NZ2/ 00455 to J.M.B. and 2015/17/N/NZ2/03360 to M.M), and by the Foundation for Polish Science (FNP; POIR.04.04.00-00-3CF0/16). Support from the National Institutes for Health (5R01GM123247, 2R01 GM114015, and 1R35 GM134864 to N.V.D.) and the Passan Foundation are acknowledged. The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 (J.W. and N.V.D.). Funding for the open access charge was provided by Shanghai Fourth People's Hospital. The authors thank the Lee group at the Korea Institute for Advanced Study and an anonymous group for their participation in RNA-Puzzles. The authors also thank the members of the Bujnicki group for technical contributions, including Stanis?aw Dunin-Horkawicz (IIMCB), Grzegorz Chojnowski (IIMCB), Wayne Dawson (IIMCB), Dorota Matelska (IIMCB), Catarina Almeida (IIMCB), Bharat Madan (IIMCB), Grzegorz Lach (IIMCB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Author contributions: E.W. conceived and supervised the project, coordinated the collaboration, and wrote the manuscript. Z.M. organized the prediction, analyzed the results, built the website, and wrote the manuscript. All other authors predicted the structures, analyzed the results, and wrote the manuscript. Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2022/8/24

Y1 - 2022/8/24

N2 - BACKGROUND: We determined circulating anti-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody titers in a vaccinated healthcare workers (HCWs) cohort from Northern Israel in the 11 months following primary vaccination according to age, ethnicity, and previous infection status. METHODS: All consenting HCWs were invited to have their IgG levels measured before vaccination and at 6 subsequent timepoints using a quantitative S1/S2 IgG assay. All HCWs with suspected coronavirus disease 2019 (COVID-19) were polymerase chain reaction (PCR) tested. We described trends in circulating IgG geometric mean concentration (GMC) by age, ethnicity, timing of boosting, and previous infection status and compared strata using Kruskall-Wallis tests. RESULTS: Among 985 vaccinated HCWs, IgG titers between 1 month post 2nd dose to pre-boosting gradually decreased in all age groups. Younger or previously infected individuals had higher initial post-vaccination IgG levels (P < .001 in both cases); differences substantially decreased or disappeared at 7-9 months, before boosting. The proportion of individuals infected prior to initiating vaccination and re-infected after dose 1 was comparable to the proportion of breakthrough infection post-dose 2 in those not previously infected (4.2 vs 4.7%). Pre-infection IgG levels in the 40 participants with breakthrough infection after dose 2 were similar to levels measured at the same timepoint in vaccinated HCWs who remained uninfected (P > .3). Post-dose3 IgG levels were more than 10-fold those 1 month post-dose 2. CONCLUSIONS: Immunity waned in all age groups and previously infected individuals, reversed by boosting. IgG titers decrease and reinfections in individuals with hybrid immunity (infection + vaccination) suggests they may also require further doses. Our study also highlights the difficulty in determining protective IgG levels.

AB - BACKGROUND: We determined circulating anti-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody titers in a vaccinated healthcare workers (HCWs) cohort from Northern Israel in the 11 months following primary vaccination according to age, ethnicity, and previous infection status. METHODS: All consenting HCWs were invited to have their IgG levels measured before vaccination and at 6 subsequent timepoints using a quantitative S1/S2 IgG assay. All HCWs with suspected coronavirus disease 2019 (COVID-19) were polymerase chain reaction (PCR) tested. We described trends in circulating IgG geometric mean concentration (GMC) by age, ethnicity, timing of boosting, and previous infection status and compared strata using Kruskall-Wallis tests. RESULTS: Among 985 vaccinated HCWs, IgG titers between 1 month post 2nd dose to pre-boosting gradually decreased in all age groups. Younger or previously infected individuals had higher initial post-vaccination IgG levels (P < .001 in both cases); differences substantially decreased or disappeared at 7-9 months, before boosting. The proportion of individuals infected prior to initiating vaccination and re-infected after dose 1 was comparable to the proportion of breakthrough infection post-dose 2 in those not previously infected (4.2 vs 4.7%). Pre-infection IgG levels in the 40 participants with breakthrough infection after dose 2 were similar to levels measured at the same timepoint in vaccinated HCWs who remained uninfected (P > .3). Post-dose3 IgG levels were more than 10-fold those 1 month post-dose 2. CONCLUSIONS: Immunity waned in all age groups and previously infected individuals, reversed by boosting. IgG titers decrease and reinfections in individuals with hybrid immunity (infection + vaccination) suggests they may also require further doses. Our study also highlights the difficulty in determining protective IgG levels.

KW - COVID-19

KW - Israel

KW - SARS-CoV-2

KW - vaccine immunogenicity

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=85129418387&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac212

DO - 10.1093/cid/ciac212

M3 - Article

C2 - 35279028

AN - SCOPUS:85129418387

SN - 1058-4838

VL - 75

SP - e572-e578

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Edelstein M, Wiegler Beiruti K, Ben-Amram H, Bar-Zeev N, Sussan C, Asulin H et al. Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021. Clinical Infectious Diseases. 2022 Aug 24;75(1):e572-e578. doi: 10.1093/cid/ciac212

Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this